Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC …,

Grant up to $17.8 million will support study of treatment-shortening regimen in drug-sensitive tuberculosis (DS-TB). Study expected to begin in 2022 …, Grant up to $17.8 million will support study of treatment-shortening regimen in drug-sensitive tuberculosis (DS-TB). Study expected to begin in 2022 …, Read More

Scroll to Top